The VHL-SMARCA2 PROTAC elicits enhanced growth inhibitory effects both in vitro and in vivo in SMARCA4mut cancer models relative to SMARCA4 wild-type (SMARCA4wt) models, in the absence of considerable tolerability issues. The gene discussed is SMARCA2; the disease is cancer.